TIDMABC

RNS Number : 6806V

ABCAM Plc

19 April 2016

 
 For immediate release   19 April 2016

ABCAM PLC

("Abcam" or "the Company")

Director / PDMR Shareholding

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, has been notified that on Monday 18 April 2016, the Trustees of the Abcam plc Share Incentive Plan ("Plan") purchased Ordinary Shares of 0.2 pence each in the Company at a price of GBP6.02 per share under the Plan's provision for Dividend Re-Investment on behalf of the persons listed below:

 
 Director                        Number of 
                                  Shares 
------------------------------  ---------- 
 Alan Hirzel, Chief Executive 
  Officer                           16 
------------------------------  ---------- 
 Jim Warwick, Chief Operating 
  Officer                           79 
------------------------------  ---------- 
 Jeff Iliffe, Chief Financial 
  Officer                           79 
------------------------------  ---------- 
 
 
 PDMR                            Number of 
                                  Shares 
------------------------------  ---------- 
 Suzanne Smith, Chief Legal 
  Officer & Company Secretary        5 
------------------------------  ----------

No consideration was paid by the above grantees in respect of the Dividend Re-Investment. The shares purchased will be subject to a minimum three year holding period.

For further information please contact:

 
                                   + 44 (0) 1223 
Abcam                                    696 000 
Suzanne Smith, Company Secretary 
 
J.P.Morgan Cazenove - Nominated      + 44 (0) 20 
 Adviser & Corporate Broker            7742 4000 
James Mitford / Chris Cargill - 
 Nominated Adviser

Notes to Editors

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam's ten offices are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHXKLFFQZFXBBE

(END) Dow Jones Newswires

April 19, 2016 09:35 ET (13:35 GMT)

Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abcam Charts.
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abcam Charts.